Clinical Trials

301 enrolled 15 charts

Lung Cancer Metastatic

NCT04918186 2026-02-12

IPROC

60 enrolled

Gynecologic

Ovarian Neoplasms

NCT03965468 2026-02-09

CHESS

96 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03768570 2026-02-02

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

82 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06769126 2026-01-22

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

900 enrolled

Small Cell Lung Carcinoma

NCT03410615 2026-01-14

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

129 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06880523 2025-12-18

SLIDE-HCC

140 enrolled

Carcinoma, Hepatocellular

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase 1 Active not recruiting

200 enrolled

Genitourinary

Prostatic Neoplasms

NCT02537418 2025-08-19

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

153 enrolled

Solid Malignancies

NCT02273375 2025-08-12

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Phase 3 Active not recruiting

1,415 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06441747 2025-07-29

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

40 enrolled

Cholangiocarcinoma

NCT06290505 2025-07-23

PALEO

54 enrolled

Esophageal Neoplasms

NCT03847649 2025-06-11

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

60 enrolled

Tumor-Agnostic

Neoplasms

NCT02788773 2025-05-15

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

52 enrolled 12 charts

Genitourinary

Prostatic Neoplasms

NCT02879162 2025-03-07

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Phase 3 Active not recruiting

140 enrolled 9 charts

Advanced Rare Tumours

NCT01993810 2024-12-18

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

330 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06094140 2024-12-03

NEO-IMPACT

20 enrolled

Pancreatic Neoplasms

NCT05718297 2024-10-08

BOUNCE

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT02870920 2023-12-08

Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer

180 enrolled 13 charts

Colorectal Neoplasms

NCT03088059 2023-11-03

UPSTREAM

Phase 2 Unknown

340 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02649686 2023-08-04

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Phase 1 Completed

15 enrolled

Breast

Breast Neoplasms

NCT03373760 2023-06-09

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

67 enrolled 17 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Completed

1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02766335 2023-05-25

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Phase 2/3 Completed

116 enrolled 23 charts

Recurrent Squamous Cell Lung Carcinoma

NCT03101475 2022-05-31

ILOC

22 enrolled

Colorectal Neoplasms

NCT03102047 2022-04-20

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

45 enrolled

Rectal Neoplasms

NCT03319316 2022-01-10

SOLUTION

Phase 2 Withdrawn